NASDAQ:TRVI

Trevi Therapeutics Stock News

etoro logo Buy TRVI
*Your capital is at risk
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Trevi Therapeutics Provides Business Updates

07:30am, Thursday, 04'th Jan 2024
NEW HAVEN, Conn. , Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Expect to enroll approximately 160 subjects and study 3 doses of Haduvio against placebo Primary efficacy endpoint is the relative change in 24-hour cough frequency of Haduvio versus placebo NEW HAVEN
The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agree
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Fin
Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Fina
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financi
Corporate presentation at 10:50 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Particip
Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global Investors LP, revealed in a Schedule 13G filing that he entered a new position in Trevi Therapeutics Inc. ( TRVI , Financial)
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE